Supplying Medical Isotopes to China and Taiwan

(AMIC; Kennewick, WA, USA) is currently in negotiations to partner with a firm headquartered in China to export isotopes as well as to produce shorter-lived isotopes in both Taiwan and China. This will provide the benefits of both higher volume availability as well as greater treatment options utilizing different medical isotope production methods currently being developed by AMIC.

Dr. Robert Schenter, AMIC chief science officer, lectured several years ago in Taiwan concerning brachytherapy for prostate cancer and "smart bullets” (precisely-targeted radioisotopes designed to kill cancer cells without harming the healthy cells), and was recently consulted to provide an update concerning medical isotopes, nuclear medicine, and the abilities of Advanced Medical Isotope to assist in the growing health issues of Taiwan and China.

"Taiwan and China are two strategic countries with which we anticipate further partnerships, and our current negotiations with forward-looking healthcare providers as well as with other life science companies appear to be evolving into solid financial opportunities. According to the recent Global Cancer Facts & Figures report, in China alone more than 350 million people smoke--more than the entire population of the United States. Enhancing the quality of life for the citizens of both of these countries is a mandate that practicing doctors in these areas insist upon, and Advanced Medical Isotope Corporation is in a unique position to assist them in fulfilling that mandate,” stated Marishka Pilch, international sales and marketing director for AMIC.

Advanced Medical Isotope is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advancing systems for local product production.


Related Links:
Advanced Medical Isotope